Statins: What next?

Tuesday 22 October 2013

Venue: Royal Society Of Medicine, 1 Wimpole Street, LONDON, W1G 0AE

A meeting in association with Heart UK

Statins are the agreed first line choice for attenuating the risk of CHD through lipid modification. Several other second line drugs have been advocated for use to address the residual risk after implementing statin therapy.

The aim of this meeting is to objectively assess the evidence base for various combinations of drugs and to critically appraise their clinical utility. This will be done in the following way:

- The results of recent trials will be assessed.

- New therapies are in development for the modulation of the lipid profile. These exciting developments will be reviewed and appraised.

Book at the bottom of this page

MSD has supported this independent educational meeting through a financial grant. MSD has provided no input into content or choice of speakers

Online registration for this event has now closed however we will be taking registrations on the day.

Please note that there may not be sufficient catering for on the day registrations.

Delegate prices:

RSM Member

Fellow £50
Associate £40
Trainee £40
Student £35
Retired fellow 40

Non RSM Member

Consultant/GP 80
AHP/Nurse/Midwife 70
Trainee 70
Student 40

9.00 am


9.15 am

Welcome and introduction
Dr Alan Rees, President, Lipids, Metabolism & Vascular Risk Section, Royal Society of Medicine

9.20 am

Mipomersen and lomitapide
Dr Handrean Soran, Department of Medicine, Central Manchester University Hospitals Foundation Trust

10.05 am

Statins and nicotinic acids
Professor Jane Armitage, Professor of Clinical Trials and Epidemiology and Group Head, Nuffield Department of Medicine

10.50 am

Tea and coffee break

11.10 am

Omega 3
Professor Parveen Yaqoob,
School Director of Research; Chemistry, Food & Pharmacy
Deputy Head of Department, Food & Nutritional Sciences, University of Reading

11.55 am

Dr Bart Staels, Professor, Faculty of Pharmacy, University of Lille, France

12.40 pm

Statins ezetimibe
Dr Adie Viljoen, Consultant Chemical Pathologist, Lister Hospital

1.25 pm


2.05 pm

Dr Alan Rees, President, Lipids, Metabolism & Vascular Risk Section, Royal Society of Medicine

2.50 pm

LDL apheresis
Dr Dev Datta, Consultant in Medical Biochemistry and Metabolic Medicine, University Hospital Llandough

3.35 pm

Completion of evaluation forms

3.40 pm

Close of meeting

Meeting ref: LIE03

CPD (Applied for)